IQVIA (IQV) Stock Price, News & Analysis

Company Overview

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management. The company maintains proprietary healthcare and commercial data assets and deploys analytics and machine learning to help clients identify patient populations, optimize trial design and accelerate product commercialization. In addition to trial execution, IQVIA offers consulting and commercialization services that support market access, medical affairs and performance improvement across product lifecycles.

Operating globally, IQVIA serves pharmaceutical and biotechnology companies, medical device manufacturers, payers, providers and government agencies across more than 100 countries. Its combination of clinical services, data resources and software platforms positions the company to support customers from early development through post‑market evidence generation and commercial operations. Because leadership and operational details can change, readers should consult the company’s filings and corporate communications for the latest governance information.

Key Stats

• Today's Range: $206.92 to $209.99
• 50-Day Range: $161.94 to $210.63
• 52-Week Range: $154.50 to $247.04
• Volume: 1.09 million shs
• Average Volume: 1.13 million shs
• Market Capitalization: $34.75 billion
• P/E Ratio: 25.80
• Dividend Yield: N/A
• Price Target: $225.71
• Consensus Rating: Moderate Buy

IQVIA Stock Analysis - MarketRank™

IQVIA scored higher than 74% of companies evaluated by MarketBeat, and ranked 176th out of 834 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

IQVIA has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on no strong buy ratings, 13 buy ratings, 3 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for IQVIA is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

IQVIA has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 11.75%

Earnings Growth

Earnings for IQVIA are expected to grow by 11.75% in the coming year, from $11.57 to $12.93 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of IQVIA is 25.80, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.07.

Price to Earnings Ratio vs. Sector

The P/E ratio of IQVIA is 25.80, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.14.

Price to Earnings Growth Ratio

IQVIA has a PEG Ratio of 1.87. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

IQVIA has a P/B Ratio of 5.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.21% of the float of IQVIA has been sold short.

Short Interest Ratio / Days to Cover

IQVIA has a short interest ratio ("days to cover") of 4.24.

Change versus previous month

Short interest in IQVIA has recently increased by 5.67%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

IQVIA does not currently pay a dividend.

Dividend Growth

IQVIA does not have a long track record of dividend growth.

News and Social Media

• Score: 4.6 / 5
• News Sentiment: 1.42

News Sentiment

IQVIA has a news sentiment score of 1.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 23 news articles for IQVIA this week, compared to 6 articles on an average week.

Search Interest

8 people have searched for IQV on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.

MarketBeat Follows

6 people have added IQVIA to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, IQVIA insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.70% of the stock of IQVIA is held by insiders.

Percentage Held by Institutions

89.62% of the stock of IQVIA is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/05/2026
• Today: 7/27/2026
• Next Earnings (Estimated): 7/28/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Business Services
• Current Symbol: NYSE:IQV
• CIK: 1478242
• Web: www.iqvia.com
• Phone: (919) 998-2000
• Fax: N/A
• Employees: 93,000
• Year Founded: 2016

Price Target and Rating

• Average Price Target for IQVIA: $225.71
• High Price Target: $255.00
• Low Price Target: $185.00
• Potential Upside/Downside: +8.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.81
• Research Coverage: 16 Analysts

Profitability

• EPS (Trailing Twelve Months): $8.07
• Trailing P/E Ratio: 25.80
• Forward P/E Ratio: 18.00
• P/E Growth: 1.87
• Net Income: $1.36 billion
• Net Margins: 8.33%
• Pretax Margin: 9.60%
• Return on Equity: 30.50%
• Return on Assets: 6.53%

Debt

• Debt-to-Equity Ratio: 2.20
• Current Ratio: 0.75
• Quick Ratio: 0.75

Sales & Book Value

• Annual Sales: $16.31 billion
• Price / Sales: 2.13
• Cash Flow: $17.89 per share
• Price / Cash Flow: 11.64
• Book Value: $38.93 per share
• Price / Book: 5.35

Miscellaneous

• Outstanding Shares: 166,900,000
• Free Float: 164,063,000
• Market Cap: $34.75 billion
• Optionable: Optionable
• Beta: 1.20